Ege. Devries et al., A PHASE-II AND PHARMACOKINETIC STUDY WITH ORAL PIRITREXIM FOR METASTATIC BREAST-CANCER, British Journal of Cancer, 68(3), 1993, pp. 641-644
Piritrexim is a lipid-soluble antifolate which, like methotrexate, has
a potent capacity to inhibit dihydrofolate reductase. We performed a
multicentre phase 11 study with piritrexim in patients with locally ad
vanced or metastatic breast cancer. Twenty-four patients of which sixt
een had received prior chemotherapy, were initially treated with 25 mg
piritrexim orally administered trice daily for four days, repeated we
ekly, with provision for dose escalation or reduction according to obs
erved toxicity. Of twenty-one patients evaluable for tumour response,
one patient achieved a partial response which lasted for 24 weeks. Thr
ee patients had stable disease during 12 weeks of treatment, seventeen
had progressive disease. Piritrexim was generally well tolerated, in
eighteen patients the dose could be escalated. Myelotoxicity was the m
ost frequent observed toxicity of this piritrexim regimen. Leucopenia
and thrombocytopenia grade 3/4 occurred in 38% of the patients sometim
e during treatment. Pharmacokinetic analysis of piritrexim in three pa
tients during the first treatment cycle, revelaed peak levels 1 to 2 h
after an oral dose, with a trend towards a higher peak plasma levels
and AUCs on the fourth dosing day compared with the first dosing day.
In conclusion, orally administered piritrexim appears to be a regimen
with little activity in patients with locally advanced or metastatic b
reast carcinoma.